Carna Biosciences, Inc.

National Cancer Center

The Kitasato Institute

Mychunter Therapeutics, Inc.

Yuko Uno

Masaaki Sawa

Tesshi Yamada

Hideki Moriyama

Satoshi Omura

Shigeki Kashimoto

Masato Iwatsuki

Kazuhiko Otoguro

Yuko Asamitsu

Aki Ishiyama

Miki Shitashige

Rei Hokari

Yusuke Kawase

The present invention provides a novel 2,4,6-substituted pyrimidine derivative, which is a compound represented by formula (I) (in the formula, ring A is a 6-membered heteroaryl group having at least one N atom optionally substituted with R1, R2, and R3; Z is an optionally substituted alkoxy group, an optionally substituted amino group, an optionally substituted heterocycloalkyl group, or an optionally substituted heteroaryl group; and R1, R2, and R3 are each independently selected from the group consisting of a hydrogen atom, a halogen atom, an optionally substituted alkyl group, an optionally substituted cycloalkyl group, an optionally substituted alkoxy group, an optionally substituted cycloalkyloxy group, an optionally substituted heterocycloalkyloxy group, an optionally substituted phenoxy group, an optionally substituted amino group, a nitro group, and a hydroxy group) or a pharmaceutically acceptable salt thereof.

Pyrimidine derivative having antimalarial activity

The present invention provides a quinazoline derivative represented by the following formula (I): wherein Rand Rrepresent a hydrogen atom, a halogen atom, or a lower alkyl group optionally having a substituent; Z represents a cycloalkyl group having a substituent or a cycloalkenyl group having a substituent; and Q represents a bicyclic heteroaryl group optionally having a substituent, or a pharmaceutically acceptable salt thereof. Since the compound has an inhibitory effect on the Wnt/&#x3b2;-catenin signaling pathway and exhibits an antitumor effect, it is useful as a medicine.

Quinazoline derivative

The present invention relates to novel bicyclic thiazole compounds that inhibit Traf2- and Nck-interacting kinase (TNIK), and as such are useful as TNIK inhibitors administered to cancer patients, especially to solid cancer patients such as colorectal cancer, pancreatic cancer, non-small cell lung cancer, prostate cancer or breast cancer. The bicyclic thiazole compounds are showed by a next formula (I). (wherein R, R, Rand Q are as defined in the specification), or a pharmaceutically acceptable salt thereof. 

Bicyclic thiazole compounds

Growing community of inventors

Kobe, Japan

Yuko Uno